UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 104

Sortiert nach

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity

Proceedings of the National Academy of Sciences - PNAS, 2015-03, Vol.112 (11), p.E1297-E1306

2015

Volltextzugriff (PDF)

Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer

Molecular cancer therapeutics, 2019-02, Vol.18 (2), p.245-256

2019

Volltextzugriff (PDF)

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

Journal of clinical oncology, 2009-01, Vol.27 (3), p.418-425

2009

Volltextzugriff (PDF)

M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis

PloS one, 2011-06, Vol.6 (6), p.e21106-e21106

2011

Volltextzugriff (PDF)

A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy

BMC cancer, 2013-04, Vol.13 (1), p.195-195, Article 195

2013

Volltextzugriff (PDF)

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors

Cancer Immunology, Immunotherapy, 2018-03, Vol.67 (3), p.445-457

2018

Volltextzugriff (PDF)

Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer

Journal of clinical oncology, 2004-09, Vol.22 (17), p.3507-3516

2004

Volltextzugriff (PDF)

342 Improving TCR-T cell function against solid tumors with immune enhancing edits

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A391-A391

2023

Volltextzugriff (PDF)

Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells

Cancer Immunology, Immunotherapy, 2012-07, Vol.61 (7), p.991-1003

2012

Volltextzugriff (PDF)

173 An in vivo CRISPR/Cas9 screening platform to identify T cell enhancing edits in distinct solid tumor microenvironments

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A103-A104

2020

Volltextzugriff (PDF)

Biologic and Immunologic Therapies for Ovarian Cancer

Journal of clinical oncology, 2003-05, Vol.21 (10 suppl), p.168s-174

2003

Volltextzugriff (PDF)

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

Gynecologic oncology, 2004-08, Vol.94 (2), p.340-351

2004

Volltextzugriff (PDF)

Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay

Journal of immunological methods, 2003-08, Vol.279 (1), p.1-15

2003

Volltextzugriff (PDF)

Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

American journal of obstetrics and gynecology, 2003-07, Vol.189 (1), p.28-36

2003

Volltextzugriff (PDF)

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer

Clinical cancer research, 2007-07, Vol.13 (13), p.4026; author reply 4026-4026

2007

Volltextzugriff (PDF)

Role of monoclonal antibodies in tumor-specific immunity

Expert opinion on biological therapy, 2007-03, Vol.7 (3), p.331-343

2007

Volltextzugriff (PDF)

Induction of ca125-specific B and T cell responses in patients injected with MAB-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo

Cancer biotherapy & radiopharmaceuticals, 2001-06, Vol.16 (3), p.187-203

2001

Volltextzugriff (PDF)

1037 Adoptive cell therapy with genetically engineered t-cells for epithelial ovarian cancer

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A511-A511

2024

Volltextzugriff (PDF)

A Novel Strategy for Off-the-Shelf T Cell Therapy Which Evades Allogeneic T Cell and NK Cell Rejection

Blood, 2021-11, Vol.138 (Supplement 1), p.1711-1711

2021

Volltextzugriff (PDF)

Abstract 5499: Necuparanib affects tumor progression and invasion in a 3D co-culture system of pancreatic cancer cells and stellate cells

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5499-5499

2015

Volltextzugriff (PDF)

NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Blood, 2020-11, Vol.136 (Supplement 1), p.32-33

2020

Volltextzugriff (PDF)

Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors

Science translational medicine, 2016-11, Vol.8 (365), p.365ra158

2016

Volltextzugriff (PDF)

Abstract 5574: In vivo model development for immune cell-based therapeutics

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5574-5574

2020

Volltextzugriff (PDF)

Using antibodies in tumour immunotherapy

Expert opinion on biological therapy, 2004-08, Vol.4 (8), p.1265-1284

2004

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Englisch
(63)
Deutsch
(41)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Humans
(29)
Life Sciences & Biomedicine
(29)
Female
(19)
Animals
(14)
Cultural Studies
(13)
Philosophy: Aesthetics
(13)
Theory Of Art
(13)
Immunotherapy
(12)
Mice
(11)
Biological And Medical Sciences
(10)
Male
(10)
Middle Aged
(10)
Oncology
(10)
Ovarian Neoplasms - Immunology
(10)
Antibodies, Monoclonal - Therapeutic Use
(9)
Ca-125 Antigen - Immunology
(9)
Immunology
(9)
Medical Sciences
(9)
Aged
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity

Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis

A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors

Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer

342 Improving TCR-T cell function against solid tumors with immune enhancing edits

Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells

173 An in vivo CRISPR/Cas9 screening platform to identify T cell enhancing edits in distinct solid tumor microenvironments

Biologic and Immunologic Therapies for Ovarian Cancer

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay

Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer

Role of monoclonal antibodies in tumor-specific immunity

Induction of ca125-specific B and T cell responses in patients injected with MAB-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo

1037 Adoptive cell therapy with genetically engineered t-cells for epithelial ovarian cancer

A Novel Strategy for Off-the-Shelf T Cell Therapy Which Evades Allogeneic T Cell and NK Cell Rejection

Abstract 5499: Necuparanib affects tumor progression and invasion in a 3D co-culture system of pancreatic cancer cells and stellate cells

NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors

Abstract 5574: In vivo model development for immune cell-based therapeutics

Using antibodies in tumour immunotherapy

Suchergebnisse filtern